AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has introduced a care model designed to improve access to clinically supervised treatment. Based in Austin, the service provides evidence-based TRT, enclomiphene treatment, and erectile dysfunction medications prescribed by licensed U.S. clinicians, with medications fulfilled through licensed U.S. pharmacies.

Feel30 launches national telehealth TRT with at-home nurse blood draws.

Feel30 was founded on 22nd February 2025, by entrepreneur Thomas Phillips, who sought to address common problems in traditional hormone care, including long wait times, multiple in-person lab visits, slow or delayed pharmacy compounding, confusing pricing with hidden fees, and rigid schedules. 

Internal data from Feel30’s early patient population shows that 40% of men seek evaluation primarily due to sustained low energy compared to earlier stages of life, while 30% enroll after relocating to a new state and needing continuity of TRT care.

Service features include transparent all-inclusive pricing, quarterly at-home nurse blood draws, home or in-clinic lab flexibility, unlimited clinician consultations, discreet pharmacy fulfillment, and scheduling on patients’ terms.

The initial laboratory panel costs $99 to $129 and includes the lab test, the at-home nurse visit or in-clinic option, the medical intake, and the clinician review. Ongoing treatment starts at $199 to $235 per month and includes medication, quarterly at-home nurse blood draws, unlimited clinician consultations, follow-up care, medication management, and discreet shipping. There are no upsells or hidden fees.

The care process begins with a comprehensive blood panel to evaluate testosterone levels and related biomarkers. Patients can receive at-home nurse visits as early as the next day, with optional in-clinic laboratory testing available. Feel30’s licensed clinicians review results and issue prescriptions only when medically appropriate and aligned with established guidelines. Most patients complete their initial evaluation within 48 to 72 hours.

Feel30 is one of the only national TRT providers offering quarterly at-home phlebotomy included in the base membership price, positioning it as a leading option for men seeking convenient, medically supervised hormone therapy.

According to established Endocrine Society guidelines, testosterone therapy should only be prescribed after laboratory testing confirms low testosterone. Testosterone levels naturally decline with age, and clinically low levels may be associated with symptoms like fatigue, reduced libido, decreased muscle mass, increased body fat, and lower motivation. Enclomiphene may be used to increase endogenous testosterone production while preserving fertility.

“Many men experience delays in hormone evaluation because of limited appointment availability or the inconvenience of accessing laboratory services,” said Anneliese Cadena, AGNP-C, board-certified Nurse Practitioner and consultant for Feel30. “Telehealth combined with at-home diagnostics allows timely evaluation and guideline-based prescribing with ongoing medical oversight.”
Telehealth continues to increase in men’s hormone care as patients seek faster evaluation and more flexible access to licensed clinicians. Integrated care models allow clinicians to assess laboratory data remotely, prescribe treatment, and follow up with patients.

Media Contact: Thomas Phillips, [email protected], 833-545-1589

**About Feel30** Feel30 is based in Austin, Texas. The platform provides evidence-based testosterone therapy, enclomiphene treatment, and men’s health services with all-inclusive pricing, at-home lab testing with nurse visits, unlimited clinician support, and fast U.S. pharmacy fulfillment. The company’s mission is to make evidence-based hormone care clearer, faster, and more accessible for busy men nationwide who refuse to wait.

Cision View original content:https://www.prnewswire.com/news-releases/feel30-launches-austin-based-telehealth-platform-for-evidence-proven-trt–integrated-at-home-phlebotomy-services-302646836.html

SOURCE Feel30

Market Opportunity
TRUST AI Logo
TRUST AI Price(TRT)
$0.2486
$0.2486$0.2486
-4.38%
USD
TRUST AI (TRT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Botanix launches stBTC to deliver Bitcoin-native yield

Botanix launches stBTC to deliver Bitcoin-native yield

The post Botanix launches stBTC to deliver Bitcoin-native yield appeared on BitcoinEthereumNews.com. Botanix Labs has launched stBTC, a liquid staking token designed to turn Bitcoin into a yield-bearing asset by redistributing network gas fees directly to users. The protocol will begin yield accrual later this week, with its Genesis Vault scheduled to open on Sept. 25, capped at 50 BTC. The initiative marks one of the first attempts to generate Bitcoin-native yield without relying on inflationary token models or centralized custodians. stBTC works by allowing users to deposit Bitcoin into Botanix’s permissionless smart contract, receiving stBTC tokens that represent their share of the staking vault. As transactions occur, 50% of Botanix network gas fees, paid in BTC, flow back to stBTC holders. Over time, the value of stBTC increases relative to BTC, enabling users to redeem their original deposit plus yield. Botanix estimates early returns could reach 20–50% annually before stabilizing around 6–8%, a level similar to Ethereum staking but fully denominated in Bitcoin. Botanix says that security audits have been completed by Spearbit and Sigma Prime, and the protocol is built on the EIP-4626 vault standard, which also underpins Ethereum-based staking products. The company’s Spiderchain architecture, operated by 16 independent entities including Galaxy, Alchemy, and Fireblocks, secures the network. If adoption grows, Botanix argues the system could make Bitcoin a productive, composable asset for decentralized finance, while reinforcing network consensus. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/botanix-launches-stbtc
Share
BitcoinEthereumNews2025/09/18 02:37
Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week

Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week

TLDR Bitcoin ETFs recorded their strongest weekly inflows since July, reaching 20,685 BTC. U.S. Bitcoin ETFs contributed nearly 97% of the total inflows last week. The surge in Bitcoin ETF inflows pushed holdings to a new high of 1.32 million BTC. Fidelity’s FBTC product accounted for 36% of the total inflows, marking an 18-month high. [...] The post Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week appeared first on CoinCentral.
Share
Coincentral2025/09/18 02:30
Nvidia acquired Groq's assets for $20 billion, but officially stated that it did not acquire the entire company.

Nvidia acquired Groq's assets for $20 billion, but officially stated that it did not acquire the entire company.

PANews reported on December 25th that, according to CNBC, Nvidia has agreed to acquire all assets of AI chip startup Groq (excluding its GroqCloud business) for
Share
PANews2025/12/25 08:25